Navigation Links
Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development
Date:2/17/2009

Renowned cancer researcher Dr. Daniel Von Hoff and his team at TGen are fervent believers in a new approach to developing novel therapies for patients with pancreatic cancer. They are guided by a rationale dubbed the "context of vulnerability." Dr. Von Hoff provides case studies and explains how this powerful paradigm has already led to promising discoveries and is changing the future of oncology drug development. The complete interview is available for download from Medelis, an oncology contract research organization providing worldwide oncology clinical trial design, management and execution.

Phoenix, AZ (PRWEB) February 17, 2009 -- Today, Medelis, Inc., a global oncology contract research organization, has published a free new downloadable abstract, "Context of Vulnerability: A Powerful New Paradigm for Targeted Drug Development." In this extensive interview, renowned oncology investigator Daniel D. Von Hoff, M.D., a founder of Medelis and a member the National Cancer Advisory Board, advocates for this powerful new drug development paradigm that is generating impressive results in the war on pancreatic cancer, the most deadly of all cancers.

"People say we have lost the war on cancer and it is so discouraging to the people who deliver the care every day, the people who are seeing those curves turn around," laments Dr. Von Hoff. "The fact is that the rising tide of cancer deaths hasn't just been stemmed - it's been turned around. Mortality, in terms of absolute number of deaths, has been down for two years in a row. It should have been going up like a rocket because we're all aging."

Dr. Von Hoff's team believes a new approach for targeted drug development, "context of vulnerability," is the key to developing powerful targeted therapeutics. The term, coined by TGen's Spryo Mousses, Ph.D., refers to the genetic configuration in a patient's tumor that makes it susceptible to a specific drug. "Context of vulnerability provides the genetic rationale for a targeted therapy," Dr. Von Hoff explains.

"If you let context of vulnerability guide drug development, you would put only those patients who have the appropriate susceptibility to the drug on trial," he says. "This optimizes your chance of seeing efficacy with a much smaller n. It's essentially how Herceptin® got approved with an n of 480. If they hadn't pre-selected patients for the context of vulnerability, estimates say that it would have taken about 23,000 patients to get the drug approved."

In the abstract, Dr. Von Hoff provides a detailed look at the promise and potential of this approach::

1. How to establish a patient's context of vulnerability;
2. How using context of vulnerability to guide drug development can improve your chance of seeing efficacy with a much smaller n;
3. Incorporating context of vulnerability as the oncologist's "sixth vital sign;"
4. A case study of context of vulnerability in use and how it improves patient care and new agent development;
5. The gap between known contexts of vulnerability and available therapeutics;
6. How CMOs can flip their drug development planning to leverage this approach;
7. Feedback from the FDA, national and international groups;
8. The promise and potential of this approach.

ABOUT DR. VON HOFF

A member of President Bush's National Cancer Advisory Board, Dr. Von Hoff's major interest is in the development of new anticancer agents both in the clinic and in the laboratory. His laboratory interests and contributions have been in the area of in vitro drug sensitivity testing to individualize treatment for the patient. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies with a focus on pancreatic cancer.

Dr. Von Hoff currently serves as Senior Investigator and Head of Translational Research at the Translational Genomics Research Institute's (TGen) Translational Drug Development Division and Head, Pancreatic Cancer Research Program in Phoenix, Arizona. He also serves as Chief Scientific Officer for U.S. Oncology and the Scottsdale Clinical Research Institute and is a founding shareholder and chair of the medical advisory board of Medelis.

ABOUT "INSIDER ABSTRACTS"

The abstract is the fifth in Medelis' complimentary "Peer Perspectives in Oncology" Q&A series, which brings together respected researchers to discuss issues that face Chief Medical Officers today.

These free abstracts are available for download at Medelis.com.

ABOUT MEDELIS

Medelis, Inc. is an oncology contract research organization providing a total solution for biotechnology and pharmaceutical companies seeking rapid drug development and approval. Medelis' medical founders, clinical trial management physicians and advisory board members, including Dan Von Hoff, James Gourzis and Michael Gordon, are internationally-recognized oncology thought and opinion leaders who understand the future of personalized medicine and threshold of credibility trials. Offerings include strategic plans for regulatory approval from phase I through NDA and complete oncology clinical trial design, management and execution.

Medelis is privately-held and located in Phoenix, Arizona with other U.S. locations in Nashville, Boston and Reno. Medelis Europe, which also delivers complete oncology drug development services from preclinical through marketing approval, is headquartered in Port Vendres, France.

###

Read the full story at http://www.prweb.com/releases/context-of-vulnerability/phase-I-phase-II-CRO/prweb2074494.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. Conventional prognostic factors fail to explain better prostate cancer survival in most Asian men
2. Survival differences by race most apparent in advanced stages of breast cancer
3. MRI finds breast cancer before it becomes dangerous
4. Investigators uncover intriguing clues to why persistent acid reflux sometimes turns into cancer
5. Pathway links inflammation, angiogenesis and breast cancer
6. Radiologists encouraged to look beyond cancer for clinically unseen diseases
7. Diet high in meat, fat and refined grains linked to risk for colon cancer recurrence, death
8. Immune deficiency linked to a type of eye cancer
9. Drop in breast cancer incidence linked to hormone use, not mammograms
10. Breast cancer prevention practices vary across Canada
11. First biomarker discovered that predicts prostate cancer outcome
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Cancer Researcher Dan Von Hoff, M.D. Advocates for "Context of Vulnerability," A Powerful New Paradigm for Targeted Drug Development 
(Date:2/22/2017)... ... 22, 2017 , ... The SeniorCare Investor will host an important webinar— Seniors ... 2017, at 1:00 PM ET. A recording of the webinar will also be made ... , If you want to find out what really happened in the seniors housing ...
(Date:2/22/2017)... ... February 22, 2017 , ... FPS is a ... PTSD. , Established in 1977, our organization was at the forefront in working ... to civilian life were evident and served as the catalyst for the establishing ...
(Date:2/22/2017)... ... February 22, 2017 , ... Alto-Shaam is pleased to ... Multi-Cook Oven offers up to four ovens in one. Control temperature, fan speed ... unmatched evenness in cooking. Alto-Shaam has partnered with Appliance Innovation to introduce this ...
(Date:2/21/2017)... ... February 21, 2017 , ... Robins & Morton celebrated ... Oklahoma, on Feb. 21. , The celebration began with a ribbon cutting event ... the construction team and tribal leadership. , Choctaw Nation Durant Regional Medical ...
(Date:2/21/2017)... Angeles, CA (PRWEB) , ... February 21, 2017 , ... ... the United States according to the American Society of Plastic Surgeons. Some patients want ... address the functionality of their nose and improve their breathing ability. The team at ...
Breaking Medicine News(10 mins):
(Date:2/22/2017)... Conn. , Feb. 22, 2017   Protein ... maker of Flublok® Influenza Vaccine , announced today ... Partnership for Influenza Vaccine Introduction (PIVI) and the Mongolian ... devastating impacts of the flu.  The doses of Flublok ... Mongolia for health care workers, ...
(Date:2/22/2017)... PUNE, India , February 22, 2017 ... Market Research, titled, "Radiology Information System Market by Type, Component, ... Forecast, 2014-2022," the radiology information system market was valued at ... million by 2022, growing at a CAGR of 5.9% from ... over three-fifths share of the total market in 2015. ...
(Date:2/22/2017)... 22, 2017  Based on its recent analysis ... Sullivan recognizes SnooZeal, Inc. with the 2017 European ... innovative product that intelligently addresses the root causes ... through the clinically proven continuous transmucosal electrical stimulation ... is one of the most accessible anti-snoring products ...
Breaking Medicine Technology: